Literature DB >> 11797774

The West Nile virus encephalitis outbreak in the United States (1999-2000): from Flushing, New York, to beyond its borders.

D S Asnis1, R Conetta, G Waldman, A A Teixeira.   

Abstract

Viruses cause most forms of encephalitis. The two main types responsible for epidemic encephalitis are enteroviruses and arboviruses. The City of New York reports about 10 cases of encephalitis yearly. Establishing a diagnosis is often difficult. In August 1999, a cluster of five patients with fever, confusion, and weakness were admitted to a community hospital in Flushing, New York. Flaccid paralysis developed in four of the five patients, and they required ventilatory support. Three, less severe, cases presented later in the same month. An investigation was conducted by the NewYork City (NYC) and New York State (NYS) health departments and the national Centers for Disease Control and Prevention (CDC). The West Nile virus (WNV) was identified as the etiologic agent. WNV is an arthropod-borne flavivirus, with a geographic distribution in Africa, the Middle East, and southwestern Asia. It has also been isolated in Australia and sporadically in Europe but never in the Americas. The majority of people infected have no symptoms. Fever, severe myalgias, headache, conjunctivitis, lymphadenopathy, and a roseolar rash can occur. Rarely, encephalitis or meningitis is seen. The NYC outbreak resulted in the first cases of WNV infection in the Western Hemisphere and the first arboviral infection in NYC since yellow fever in the nineteenth century. The WNV is now a public health concern in the United States.

Entities:  

Mesh:

Year:  2001        PMID: 11797774     DOI: 10.1111/j.1749-6632.2001.tb02694.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  28 in total

1.  Correlation between breakdown of the blood-brain barrier and disease outcome of viral encephalitis in mice.

Authors:  Aaron L Olsen; John D Morrey; Donald F Smee; Robert W Sidwell
Journal:  Antiviral Res       Date:  2006-12-20       Impact factor: 5.970

2.  Flavivirus RNA cap methyltransferase: structure, function, and inhibition.

Authors:  Lihui Liu; Hongping Dong; Hui Chen; Jing Zhang; Hua Ling; Zhong Li; Pei-Yong Shi; Hongmin Li
Journal:  Front Biol (Beijing)       Date:  2010-08-01

3.  Vector competence of Culex neavei and Culex quinquefasciatus (Diptera: Culicidae) from Senegal for lineages 1, 2, Koutango and a putative new lineage of West Nile virus.

Authors:  Gamou Fall; Mawlouth Diallo; Cheikh Loucoubar; Ousmane Faye; Amadou Alpha Sall
Journal:  Am J Trop Med Hyg       Date:  2014-02-24       Impact factor: 2.345

4.  Health-care provider preferences for time-sensitive communications from public health agencies.

Authors:  Debra Revere; Ian Painter; Mark Oberle; Janet G Baseman
Journal:  Public Health Rep       Date:  2014       Impact factor: 2.792

5.  West Nile virus infection and its neurological manifestations.

Authors:  Ken Madden
Journal:  Clin Med Res       Date:  2003-04

6.  Risk factors for encephalitis and death from West Nile virus infection.

Authors:  K Murray; S Baraniuk; M Resnick; R Arafat; C Kilborn; K Cain; R Shallenberger; T L York; D Martinez; J S Hellums; D Hellums; M Malkoff; N Elgawley; W McNeely; S A Khuwaja; R B Tesh
Journal:  Epidemiol Infect       Date:  2006-05-04       Impact factor: 2.451

Review 7.  West Nile virus and its emergence in the United States of America.

Authors:  Kristy O Murray; Eva Mertens; Philippe Despres
Journal:  Vet Res       Date:  2010 Nov-Dec       Impact factor: 3.683

8.  Southern California neuroinvasive West Nile virus case series.

Authors:  Chirag B Patel; Bhavesh V Trikamji; Glenn E Mathisen; Shrikant K Mishra
Journal:  Neurol Sci       Date:  2017-11-08       Impact factor: 3.307

9.  Dengue in the context of "safe blood" and global epidemiology: to screen or not to screen?

Authors:  Marion C Lanteri; Michael P Busch
Journal:  Transfusion       Date:  2012-08       Impact factor: 3.157

10.  The relative contribution of antibody and CD8+ T cells to vaccine immunity against West Nile encephalitis virus.

Authors:  Bimmi Shrestha; Terry Ng; Hsien-Jue Chu; Michelle Noll; Michael S Diamond
Journal:  Vaccine       Date:  2008-02-20       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.